Cargando…

Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma

Detalles Bibliográficos
Autores principales:	Gao, Yuan, Yu, Liqing, Miao, Hongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556073/ https://www.ncbi.nlm.nih.gov/pubmed/37798307 http://dx.doi.org/10.1038/s41392-023-01611-4

Ejemplares similares

Deconvoluting cellular neighborhoods in pancreatic ductal adenocarcinoma
por: Lal, Jessica Castrillon
Publicado: (2022)

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021)

Targeting metabolic/epigenetic pathways: a potential strategy for cancer therapy in diffuse intrinsic pontine gliomas
por: Zhao, Kun, et al.
Publicado: (2020)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
por: Zhang, Yue, et al.
Publicado: (2022)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Modulating serine palmitoyltransferase‐deoxysphingolipid axis in cancer therapy
por: Xiang, Yuancai, et al.
Publicado: (2020)

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
por: Hou, Wanting, et al.
Publicado: (2022)

Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities
por: Ryan, Tristram A. J., et al.
Publicado: (2022)

Pancreatic tumor initiation: the potential role of IL-33
por: Huang, Xing, et al.
Publicado: (2021)

EDS1 modules as two-tiered receptor complexes for TIR-catalyzed signaling molecules to activate plant immunity
por: Li, Jia, et al.
Publicado: (2022)

Immune receptor mimicking hormone receptors: a new guarding strategy
por: Liu, Xueru, et al.
Publicado: (2023)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
por: Delma, Mohamed Islam
Publicado: (2020)

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

FAP senescence: a critical event in muscle regeneration
por: Kang, Xia, et al.
Publicado: (2023)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

The curious case of IL‐33 in homeostasis and infection
por: Nadafi, Reza, et al.
Publicado: (2020)

Dietary intervention, a promising adjunct for cancer therapy
por: Shi, Rongchen, et al.
Publicado: (2020)

Intestinal CD8(+) tissue‐resident memory T cells: From generation to function
por: Cheng, Liqing, et al.
Publicado: (2022)

IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma
por: Fan, Liwen, et al.
Publicado: (2022)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma
por: Haney, Staci L., et al.
Publicado: (2019)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

Hydrogen sulfide controls peripheral nerve degeneration and regeneration: a novel therapeutic strategy for peripheral demyelinating disorders or nerve degenerative diseases
por: Jung, Junyang, et al.
Publicado: (2014)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Ketogenic diet: new avenues to overcome colorectal cancer
por: Xiang, Yuancai, et al.
Publicado: (2022)

Macrophages assemble! But do they need IL‐4R during schistosomiasis?
por: Rückerl, Dominik, et al.
Publicado: (2019)

Gasdermin D as a cellular switch to orientate immune responses via IL-33 or IL-1β
por: Chauvin, Camille, et al.
Publicado: (2022)

Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma
por: Vaz, Arokia Priyanka, et al.
Publicado: (2015)

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
por: Azad, Abul, et al.
Publicado: (2016)

Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

DC activated via dectin-1 convert Treg into IL-17 producers
por: Osorio, Fabiola, et al.
Publicado: (2008)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces
por: Smole, Ursula, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i355knj23islvp7akqn1dk3fne